Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Korro Bio (KRRO) over the last 7 years, with Q3 2025 value amounting to $24.2 million.

  • Korro Bio's Cash & Equivalents fell 6178.43% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year decrease of 6178.43%. This contributed to the annual value of $55.6 million for FY2024, which is 6651.04% down from last year.
  • As of Q3 2025, Korro Bio's Cash & Equivalents stood at $24.2 million, which was down 6178.43% from $33.6 million recorded in Q2 2025.
  • Over the past 5 years, Korro Bio's Cash & Equivalents peaked at $169.2 million during Q1 2021, and registered a low of $24.2 million during Q3 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $55.6 million (2024), whereas its average is $75.1 million.
  • In the last 5 years, Korro Bio's Cash & Equivalents tumbled by 7055.43% in 2022 and then skyrocketed by 35729.78% in 2023.
  • Korro Bio's Cash & Equivalents (Quarter) stood at $79.6 million in 2021, then crashed by 54.38% to $36.3 million in 2022, then soared by 357.3% to $166.2 million in 2023, then crashed by 66.51% to $55.6 million in 2024, then crashed by 56.59% to $24.2 million in 2025.
  • Its Cash & Equivalents stands at $24.2 million for Q3 2025, versus $33.6 million for Q2 2025 and $64.1 million for Q1 2025.